Brian HicksPosted September 13, 2013
Congress is running out of time to reach a decision on the debt ceiling. But there are even more pressing issues facing the economy as well...
Briton RylePosted September 13, 2013
Diamond investing is starting to pick up steam, and the first diamond ETF may make it a very popular investment choice...
Brian HicksPosted September 12, 2013
I've found five tech companies, currently still private, that may be headed towards a public offering within the next 12 months...
Christian DeHaemerPosted September 12, 2013
There has been a lot of talk lately about robots and robotics and the future of the global workforce. Christian DeHaemer explains...
Briton RylePosted September 12, 2013
Groupon's (NASDAQ: GRPN) IPO was a well-publicized flop. Will LivingSocial take heed, or will the digital coupon company go public as well?
Brian HicksPosted September 12, 2013
According to Jeffrey Gundlach, the Fed is making a huge mistake in deciding to taper. He recommends a different strategy...
Jason StutmanPosted September 11, 2013
By sacrificing margins, a few tech companies have ruthlessly been swiping market share from their highfalutin competitors. The verdict is in... and consumers want cheap.
Briton RylePosted September 11, 2013
Analyst Briton Ryle tells readers why he thinks Ford has real good shot at hitting $25 over the next six months...
Brian HicksPosted September 11, 2013
The most recent set of unemployment numbers showed some pretty disappointing results. How will this affect the Fed's meeting next week?
Briton RylePosted September 11, 2013
Mortgage lenders are being forced to scale back sooner than expected. Is this a bad sign for the housing recovery?
Christian DeHaemerPosted September 10, 2013
The great irony, of course, is that the unlock rules were created to protect the small investor. In reality, the little guy ends up knowing just enough information to burn him.
Brian HicksPosted September 10, 2013
Oncolytics Biotech Inc. (NASDAQ: ONCY) has had success with its tumor-reducing lung cancer drug and could be a buyout target...